We met with Chris Wigley, CEO and Sir Mark Caulfield, Chief Scientist at Genomics England, at the first Genomics England Research conference taking place in November 2019 in London. We started by asking them how Genomics England is getting on with their objectives.
A new study by Northwestern Medicine has become the first to compare gene expression levels in African American populations by studying the levels of mRNA expressed in the liver. Previous studies have compared only African and European individuals separately and this study aimed to address the “grey” area of mixed ethnicities.
Changing Attitudes to Cannabis Cannabis is now legalised for recreational use in 11 US states and attitudes around its risk are changing rapidly. Between 2002 and 2014, the percentage of adults in the US who perceived cannabis use as risky declined from 50% to 33%. However, as cannabis usage becomes more widespread the health risks […]
D4: Pharma is a highly-select gathering of 80-100 very senior and experienced pharma professionals responsible for making important decisions, as well as turning innovation and new ideas into measurable progress.
Maize is one of the most economically important crops globally and much effort has been spent generating the high quality B73 reference genome. However, the 10 chromosome, 2.3 gigabase (Gb) B73 reference genome was a substantial challenge due to the fact it is comprised of 85% transposable elements, 75% of which are long terminal […]
Independent US Food and Drug Administration (FDA) advisors unanimously backed Celltrion’s new Rituxan biosimilar recently, potentially allowing the company to threaten the sales dominance of Roche’s top drug.
ASCO checkpoint inhibitor battle between Merck and Roche highlights the pitfalls in directly comparing clinical trial results in the era of precision medicine.
Precision medicine is showing significant signs of success across tumour types.
Dr. Mark McClellan joined Johnson & Johnson’s board of directors after leaving the FDA, but the connection often isn’t mentioned in research papers or public events.
Researchers have created an artificial intelligence system for predicting, not simply tracking, potential side effects from drug combinations.
Scientists have discovered a “big bang” of Alzheimer’s disease — the precise point at which a healthy protein becomes toxic but has not yet formed deadly tangles in the brain.
A new technique for precisely targeting molecules within cells is paving the way for safer medicines that are free of side effects.